Mycobacterial Diseases

Mycobacterial Diseases
Open Access

ISSN: 2161-1068

+44 1478 350008

Haruaki Tomioka

Haruaki Tomioka

Haruaki Tomioka
Professor and Chairman, Department of Microbiology and Immunology
Shimane University School of Medicine, Japan


I am the professor of Department of Microbiology and Immunology,Shimane University School of Medicine, Izumo, Japan. I am acting or have ever acted as a director of Japanese Society for Bacteriology, Japanese Association for Infectious Diseases, and Japanese Society for Tuberculosis, and presently acting as a district leader of these three academic societies in the western part of Japan. I am also an associate editor of three international journals, “Microbiology and Immunology”, “Journal of Infection and Chemotherapy”, and “Chemotherapy Research and Practice”. I am acting or have ever acted as the reviewers for the following journals: J Infect Dis, Infect Immun, Antimicrob Agents Chemother, J Antimicrob Chemother, Int J Antimicrob Agents, Clin Exp Immunol, Future Microbiol, Biochim Biophys Acta, J Med Microbiol, Cell Mol Biol, FEMS Microb Lett, Expert Opin Pharmacol, Expert Opin Invest Drugs, BMC Infect Dis, Lung, J Pharm Pharmacol, etc. In addition, I have ever acted as an executive editor of Curr Pharm Des (IF=5.3) and edited the special issue entitled “Antimycobacterial Drugs: Current Status and Future Prospects”. I have also acted as an editor of the special immunology book entitled “Current Topics on the Profiles of Host Immunological Responses to Mycobacterial Infections”, which was published by Research Signpost. I have published more than 250 scientific articles in peer reviewed international journals and medical book chapters.

Research Interest

Virulence factors of mycobacterial pathogens, mechanisms of macrophage bactericidal activity against mycobacterial organisms, drug targets in Mycobacterium tuberculosis for development of antituberculous drugs, molecular epidemiology of nontuberculous mycobacterial infections
Evaluation of in vitro and in vivo activities of new antimycobacterial agents.